6533b85cfe1ef96bd12bc78f
RESEARCH PRODUCT
Two large steps forward, one small step back
Peter R. GalleMarcus-alexander Wörnssubject
SorafenibOncologymedicine.medical_specialtyHepatologybusiness.industryGastroenterologySorafenib treatmentmedicine.diseasedigestive system diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisRegorafenibInternal medicineHepatocellular carcinomaCarcinomamedicineAdvanced disease030211 gastroenterology & hepatologyStage (cooking)Nivolumabbusinessmedicine.drugdescription
In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-04 | Nature Reviews Gastroenterology & Hepatology |